Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E19.75 EPS (ttm)2.18 Insider Own0.04% Shs Outstand5.87B Perf Week-4.77%
Market Cap252.94B Forward P/E13.95 EPS next Y3.09 Insider Trans-28.54% Shs Float5.86B Perf Month0.37%
Income13.15B PEG2.63 EPS next Q0.75 Inst Own73.00% Short Float0.85% Perf Quarter14.53%
Sales53.24B P/S4.75 EPS this Y68.20% Inst Trans-0.01% Short Ratio2.44 Perf Half Y18.69%
Book/sh11.89 P/B3.63 EPS next Y3.48% ROA13.40% Target Price42.47 Perf Year18.66%
Cash/sh2.29 P/C18.83 EPS next 5Y7.52% ROE33.20% 52W Range33.20 - 45.81 Perf YTD19.05%
Dividend1.36 P/FCF30.59 EPS past 5Y10.40% ROI11.00% 52W High-5.87% Beta0.88
Dividend %3.15% Quick Ratio0.90 Sales past 5Y-0.80% Gross Margin78.90% 52W Low29.88% ATR0.78
Employees90200 Current Ratio1.20 Sales Q/Q4.40% Oper. Margin25.40% RSI (14)45.66 Volatility2.96% 1.66%
OptionableYes Debt/Eq0.58 EPS Q/Q27.90% Profit Margin42.30% Rel Volume1.05 Prev Close43.78
ShortableYes LT Debt/Eq0.41 EarningsOct 30 BMO Payout34.80% Avg Volume20.41M Price43.12
Recom2.70 SMA20-2.19% SMA501.12% SMA20013.64% Volume21,488,142 Change-1.51%
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Oct-15-18 07:16PM  US wants drug prices in TV ads: 'Patients deserve to know' Associated Press
05:07PM  Trump's Drug-Ad Price Shaming Won't Fix the Problem Bloomberg
12:09PM  3 Healthcare Stocks to Buy Amid the Carnage InvestorPlace
11:16AM  Drugmakers will soon talk about price in ads but not as explicitly as Trump administration wants CNBC
09:30AM  PFE or NVO: Which Is the Better Value Stock Right Now? Zacks
08:04AM  2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better Motley Fool
Oct-13-18 12:21PM  Midterms And The Stock Market: Potential Winners, Losers From The Coming Election Benzinga
Oct-12-18 05:38PM  Winners and losers Yahoo Finance Video
03:10PM  Invest Like Warren Buffett with These Stocks & ETF Zacks
08:20AM  3 Big Pharma Stocks Racing Along the Road to China Motley Fool
08:12AM  Pfizer settles New York probe into 'deceptive' copay coupons Reuters
Oct-11-18 05:34PM  Why a Peninsula cancer fighter soared nearly 40% after record-breaking IPO American City Business Journals
01:40PM  Pfizer settles New York probe into 'deceptive' copay coupons Reuters
12:15PM  Pfizer settles false advertising charges American City Business Journals
11:56AM  Pfizer to pay $700,000 to settle 'deceptive advertising' charges; stock drops to pace Dow losers MarketWatch
10:01AM  Company News For Oct 11, 2018 Zacks
09:50AM  Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus Zacks
Oct-10-18 01:43PM  Final trades: Verizon, EOG Resources, Arconic & Pfizer CNBC Videos
10:19AM  MARKETS: Stocks at the Rubicon, as Intel leads the Dow lower, but Merck, Pfizer at 17-year highs Yahoo Finance Video
10:12AM  Myriad Genetics shares soar 7% on news it will conduct testing for Pfizer breast cancer treatment MarketWatch
09:00AM  Why Pfizer Stock Is Likely Seeing Big Buying Investopedia
07:56AM  The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares Benzinga
Oct-09-18 10:54AM  [$$] Pfizer Prepares for CEO Transition With Executive Suite Changes The Wall Street Journal
09:05AM  Pfizer Announces Executive Leadership Team Business Wire
08:14AM  The Zacks Analyst Blog Highlights: Apple, Microsoft, Pfizer, Caterpillar and ConocoPhillips Zacks
Oct-08-18 04:20PM  Dow Rallies Back, S&P 500 Retakes Key Support As Tech Stocks Fall Investor's Business Daily
11:37AM  Top Stock Reports for Apple, Microsoft & Pfizer Zacks
10:40AM  The Uphill Fight Against Fake Prescription Drugs The Wall Street Journal
10:29AM  Health Care Digest: Upsized record IPO, e-cigarette questions, a CEO Dance and more American City Business Journals
06:00AM  Pfizer May Rise 8% to Highest Price Since 2000 Investopedia
12:08AM  AP FACT CHECK: Trump fudges history on black vote, drug cost Associated Press
Oct-07-18 03:41PM  IPO Outlook For The Week: Biotechs, Batteries And Business Solutions Benzinga
Oct-06-18 02:17PM  AP FACT CHECK: Trump on Kavanaugh accuser, drug prices, vets Associated Press
Oct-05-18 11:23AM  Rising Yields Pose Risk to Large-Cap Pharma's Red-Hot Rally Bloomberg
09:57AM  Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data Zacks
09:11AM  Dow 30 Stock Roundup: Boeing Wins $9.2B Pilot Training Deal, Intel Keeps '18 View Zacks
Oct-04-18 09:49AM  5 Reasons Why Investors Should Bet on Pfizer (PFE) Stock Zacks
09:19AM  Better Buy: Gilead Sciences, Inc. vs. Pfizer Motley Fool
03:20AM  Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US Moody's
Oct-03-18 06:09PM  Merck CEO sees a disintermediation in pharma like the cable industry Yahoo Finance
10:23AM  Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs Zacks
07:11AM  [$$] Lex letter from New York: chiefs checked Financial Times
07:00AM  Wide Moat Surrounds Pfizer's Solid Foundation Morningstar
02:06AM  With Hemlibra, Roche seeks to break into tight hemophilia circle Reuters
Oct-02-18 03:16PM  The 5 Best Dow Jones Stocks to Buy Now InvestorPlace
09:48AM  Pfizer's CEO Ian Read to Step Down Next Year, COO to Succeed Zacks
09:40AM  Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year? Zacks
09:15AM  Why Pfizer (PFE) is a Great Dividend Stock Right Now Zacks
09:14AM  QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite Zacks
12:15AM  [$$] Since 2000 GE has paid $6bn in adviser fees. Was it worth it? Financial Times
Oct-01-18 11:34PM  [$$] Pfizer: pill will Financial Times
11:00PM  [$$] EpiPen dearth shows company and regulator failure Financial Times
08:38PM  [$$] Pfizer Counts on Pipeline to Bring Growth The Wall Street Journal
08:38PM  [$$] Pfizer CEO Read to Step Aside at Years End The Wall Street Journal
08:05PM  PRESS DIGEST- British Business - Oct 2 Reuters
05:53PM  Business Highlights Associated Press
04:25PM  Drugmaker Pfizer's CEO Read to be replaced by COO Bourla Associated Press
04:08PM  Dow, S&P 500 End Higher on New Nafta Deal; Nasdaq Slips
02:58PM  Pfizer to replace longtime CEO Read with veteran Bourla Reuters
02:36PM  Pfizer to replace longtime CEO Read with veteran Bourla Reuters
01:38PM  Pfizer to replace longtime CEO Read with veteran Bourla Reuters
01:32PM  Pfizer's Incoming CEO Represents Pipeline Push Over Dealmaking Bloomberg
12:30PM  Scientists behind game-changing cancer immunotherapies win Nobel medicine prize Reuters
12:03PM  Tesla Produced A Record Number of Vehicles in Q3, Report Says: LIVE MARKETS BLOG
11:54AM  Pfizer CEO Ian Read to Resign InvestorPlace
11:12AM  Pfizer CEOs Transition Leaves Wall Street Divided on M&A Strategy Bloomberg
11:01AM  GEs CEO is out after only a year, and Wall Street is thrilled Quartz
10:04AM  Pfizer's Next CEO May Have to Pull Off Some Bold Deals Bloomberg
09:43AM  Pfizer Says CEO Ian Read to Retire; COO Albert Bourla Will Lead Group From 2019
09:00AM  [$$] Stocks to Watch: GE, Tesla, Pfizer, Facebook and More The Wall Street Journal
08:56AM  Pfizer CEO set to resign, replacement named American City Business Journals
08:20AM  [$$] Revamped Nafta deal gives S&P 500 shot at record high Financial Times
07:40AM  [$$] Pfizer CEO Read to Step Aside at Year's End The Wall Street Journal
07:39AM  Pfizer says CEO Ian Read will retire at the end of the year Fox Business Videos
07:32AM  Pfizer replaces longtime CEO Read with veteran Bourla Reuters
07:13AM  [$$] Ian Read to step aside as Pfizer chief executive Financial Times
07:02AM  [$$] Pfizer Counts on Pipeline to Bring Growth The Wall Street Journal
06:49AM  Pfizer announces Dr. Albert Bourla will succeed CEO Ian Read effective January 1 CNBC
06:45AM  Pfizer Announces CEO Succession Business Wire
Sep-30-18 08:25PM  [$$] Lets Throw a Patent-Burning Party The Wall Street Journal
07:01AM  Better Buy: Novavax, Inc. vs. Pfizer Inc. Motley Fool
05:00AM  People Treat Animals Like Parts of Their Family. Henry Schein Is Spinning Off Its Pet-Health Business
Sep-28-18 05:47PM  Final Trades: T, DIS & more CNBC Videos
05:45PM  Pfizer (PFE) Stock Moves 0.27%: What You Should Know Zacks
11:30AM  Stocks - Tesla Tumbles in Pre-market; Eli Lilly, BlackBerry Gain
10:54AM  Pfizer's (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval Zacks
10:07AM  Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs Zacks
09:48AM  Women Health a Prime Concern Worldwide: 3 Stocks in Focus Zacks
08:10AM  The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results Benzinga
Sep-27-18 06:29PM  Pfizer's lung cancer drug gets FDA approval Reuters
05:53PM  Pfizer's lung cancer drug get FDA nod Reuters
05:41PM  U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Business Wire
02:25PM  MannKind Stock History Motley Fool
01:09PM  Pfizer Declares 34-Cent Fourth-Quarter 2018 Dividend Business Wire
07:34AM  Trade of the Day: Pfizer Stock Rallies Too Far, Too Fast InvestorPlace
Sep-25-18 10:23AM  AstraZeneca's Imfinzi Gets EU Nod for Early-Stage Lung Cancer Zacks
08:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within Dorchester Minerals, Teladoc, Pfizer, Intercontinental Exchange, General Electric, and Prospect Capital New Research Emphasizes Economic Growth GlobeNewswire
Sep-24-18 03:11PM  AP investigation: Drug prices going up despite Trump promise Associated Press
09:52AM  Resurgent Pfizer Stock Testing 19-Year Resistance Investopedia
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Merck KGaA; and Leap Therapeutics, Inc., as well as development agreement with Antares Pharma, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dolsten MikaelPresident R&DSep 13Option Exercise24.56181,7124,462,167234,299Sep 17 04:08 PM
OLSON LAURIE JExecutive Vice PresidentAug 13Sale41.0010,214418,77472,672Aug 14 05:04 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 03Sale39.5125,6421,013,171102,412Aug 06 03:19 PM
GOETTLER MICHAELGroup PresidentAug 01Sale39.7019,198762,11611,924Aug 03 03:38 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerAug 01Sale40.1626,8141,076,93383,846Aug 03 03:36 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentAug 01Sale40.0420,942838,5724,643Aug 03 03:35 PM
DAMELIO FRANK AExecutive Vice PresidentAug 01Sale40.00150,4846,019,360337,391Aug 03 03:33 PM
SUSMAN SALLYExecutive Vice PresidentJul 20Sale37.2240,3811,502,925115,096Jul 24 01:09 PM
READ IAN CChairman & CEOJul 16Sale37.36486,75318,186,315659,440Jul 17 04:59 PM
OLSON LAURIE JExecutive Vice PresidentJun 06Sale36.4519,000692,58282,886Jun 08 01:11 PM
CORNWELL W DONDirectorJun 04Sale36.405,223190,1170Jun 05 04:44 PM
READ IAN CChairman & CEOMay 01Sale36.01132,3124,764,0811,144,703May 03 04:19 PM
JOHNSON RADY AExecutive Vice PresidentMar 13Sale36.5527,323998,66643,178Mar 14 05:19 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 13Sale36.8950,0001,844,39883,857Mar 14 05:13 PM
Dolsten MikaelPresident R&DMar 09Sale36.5969,6992,550,39451,185Mar 12 05:01 PM
HILL CHARLES HExecutive Vice PresidentMar 06Sale35.7642,3931,515,98557,328Mar 07 04:09 PM
Dolsten MikaelPresident R&DMar 02Sale35.8513,986501,398120,884Mar 05 09:23 AM
HILL CHARLES HExecutive Vice PresidentFeb 28Option Exercise27.37101,8722,788,237207,942Mar 02 03:24 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37121,1453,315,739362,707Mar 02 04:10 PM
OLSON LAURIE JExecutive Vice PresidentFeb 28Option Exercise27.3738,5461,055,004132,702Mar 02 04:02 PM
READ IAN CChairman & CEOFeb 28Option Exercise27.37649,78017,784,4791,774,184Mar 02 04:03 PM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.37110,1323,014,313245,362Mar 02 04:03 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50239,801Mar 02 03:44 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50285,910Mar 02 03:44 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3746,8061,281,080171,276Mar 02 03:44 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 28Option Exercise27.37104,6262,863,614384,219Mar 02 03:44 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37209,2515,727,200655,161Mar 02 03:24 PM
BOURLA ALBERTChief Operating OfficerFeb 28Option Exercise27.3739,9231,092,693184,120Mar 02 03:24 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3733,040904,305136,847Mar 02 03:24 PM
Dolsten MikaelPresident R&DFeb 28Option Exercise27.37198,2385,425,774293,352Mar 02 03:24 PM
HILL CHARLES HExecutive Vice PresidentFeb 28Sale36.8326,779986,292181,163Mar 02 03:24 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27Sale37.0333,3681,235,591135,230Feb 28 06:14 PM
Dolsten MikaelPresident R&DFeb 27Sale37.0464,5872,392,31395,114Feb 28 06:04 PM
CORNWELL W DONDirectorFeb 27Sale37.0530011,1150Feb 28 01:29 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 26Sale37.199,510353,67717,770Feb 27 07:38 PM
CORNWELL W DONDirectorFeb 26Sale36.741,45853,5640Feb 28 01:29 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9043,520822,528223,733Feb 27 08:59 PM
READ IAN CChairman & CEOFeb 24Option Exercise19.83903,55917,917,2651,560,007Feb 27 08:58 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9015,716297,03290,222Feb 27 07:53 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456206,972Feb 27 07:51 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9015,885300,22762,848Feb 27 07:43 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9028,288534,643112,081Feb 27 07:43 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456313,499Feb 27 07:43 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 24Option Exercise18.9015,957301,58736,959Feb 27 07:38 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 24Option Exercise18.9039,555747,590143,152Feb 27 07:38 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9065,2801,233,792122,609Feb 27 07:38 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90174,0813,290,131225,265Feb 27 07:32 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9028,288534,643116,769Feb 27 07:30 PM
BOURLA ALBERTChief Operating OfficerFeb 24Option Exercise18.9025,387479,814158,170Feb 27 07:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90174,0813,290,131511,470Feb 27 07:30 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 15Sale37.006,750249,750103,458Dec 18 06:17 PM
JOHNSON RADY AExecutive Vice PresidentDec 15Sale37.078,000296,56046,963Dec 18 06:17 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentNov 01Sale34.947,350256,809110,082Nov 02 07:03 PM